About AbbVie Inc
- Industry: Biotechnology
- Exchange: NEW YORK STOCK EXCHANGE, INC.
- Country: US
- Website: https://www.abbvie.com/
Frequently Asked Questions
What is the 52-week range for ABBV?
The 52-week high is $269.39 and the 52-week low is $190.75.
What is the P/E ratio for ABBV?
The Price to Earnings (P/E) ratio is 72.79.
What is the dividend yield for ABBV?
The indicated annual dividend yield is 4.47%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 95.59%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 9.80%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 94.44.
Analyst Recommendation Trends
Wall Street analyst consensus for ABBV over the last few months:
Latest ABBV News
How to Create a Million-Dollar Stock Portfolio
Successful stock investors have one thing in common: the power of compounding.
How Much Does a 58-Year-Old Need Invested to Replace a $160,000 Salary With Dividends?
Replacing a $160,000 salary with dividends at 58 sounds like a single math problem, but the required portfolio swings by millions depending on which yield tier you choose, and the tier that demands the least capital up front carries a hidden cost that grows every year.
Prediction: Eli Lilly Could Be the Next $2 Trillion Drugmaker
Eli Lilly just posted a 47.7% revenue surge while rivals like Novo Nordisk are watching earnings fall, and a fresh pipeline catalyst could push Lilly toward a valuation Wall Street has only seen from two companies in history.
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie's FDA approval of Juvmo expands its Parkinson's portfolio, with a commercial launch targeted for October 2026.
J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch
JNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.
8 Of 11 Sectors Rise Friday As Growth Leads
Friday's regular session has eight sectors higher and three lower, with growth sectors holding two of the top three positions. The leaders are clustered, with less than a quarter-point separating the top three sectors.
How Has Pfizer's Story Changed?
Pfizer's revenue over the past twelve months was 0.2% lower than a year earlier. When sales are flat, look at what management leads with on earnings calls to see where it expects growth. Since early 2025, Pfizer's management has changed what it leads with. It used to lead with the work of absorbing a company it had bought. It now leads with drugs it has not launched. What was that deal.
AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?
JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.
AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval
AbbVie has delivered a powerful 187.5% total return over the past 5 years, so the current US$261.59 share price naturally raises a question for investors who care about cash generation. With fresh drug approvals, pipeline updates and new partnerships in the headlines, the key issue now is whether AbbVie’s cash flows are strong enough and durable enough to underpin where the stock trades today. That 187.5% 5 year return puts real pressure on the valuation question, because a move of that size...
3 takeaways from a European obesity scientific meeting
Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.
What Is The Options Market Telling Us About Eli Lilly Stock?
Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial and total body repigmentation through week 76.
Regeneron And Sanofi Announce A Win-Win Collaboration Expansion
Regeneron and Sanofi expand antibody pact targeting IL-4/IL-13 inflammation therapies, with $1B upfront and up to $7B milestones. Click to read my analysis for more.
5 Solid Dividend Stocks to Buy Now
Five dividend payers across four sectors promise to keep raising payouts through the next downturn, but one of them carries a GAAP payout ratio above 100% and a negative book value that would alarm most income investors at first glance.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test)
With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell?
AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.
AbbVie Presents Data From Its Current Phase 3 Viti-Up-1, Viti-Up-2 Trials Of RINVOQ At 2026 European Academy Of Dermatology And Venereology Congress
AbbVie (NYSE: ABBV) today announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ® (upadacitinib; 15 mg once daily) in non-segmental vitiligo (NSV), showing continued facial
Was The Run In JNJ Stock Hiding In Plain Sight?
Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.
AbbVie Stock: Buy, Sell, or Hold in October?
The pharmaceutical giant still looks like a stable long-term investment.
3 Healthcare Dividend Stocks Offering More Than Just Income
AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.
What Does AbbVie (ABBV) Need To Prove After Its Eczema Drug And AI Update?
AbbVie (NYSE: ABBV) reported Phase 2 APEX Part B data for zumilokibart in moderate to severe atopic dermatitis at the EADV Congress. The company selected a mid dose of zumilokibart for Phase 3 development after the study showed significant clinical improvements in patients. AbbVie joined the Antibody Developability Consortium as a founding member and started a new AI driven R&D collaboration with Valkai. The zumilokibart Phase 2 results and AbbVie’s new AI alliances matter, but investors...
What Is Merck Stock's Biggest Opportunity?
Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra
1 Profitable Stock to Keep an Eye On and 2 Facing Challenges
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates
AbbVie Inc. (NYSE:ABBV) announced clinical trial data on Wednesday for two pipeline candidates, highlighting progress in its immunology and metabolic disease portfolios. The pharma giant shared encouraging Phase 2
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
AbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting (Milan, Italy; September 28 – October 2). The study evaluated the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, an investigational long-acting amylin analog, in adults with a mean body m
Eaton, AMD, SpaceX And A Health Care Stock: CNBC’s ‘Final Trades’
CNBC traders picked Eaton, SpaceX, AbbVie and AMD, citing analyst support, SpaceX’s Starship launch and AbbVie’s FDA drug approval.
Abbvie Shared Detailed Results From The Multiple Ascending Dose Part Of Its Phase 1 Study Evaluating ABBV-295 At EASD Annual Meeting, Showing Favorable Tolerability And Pharmacokinetic Profile
AbbVie (NYSE:ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
AbbVie (NYSE: ABBV) today announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis (AD) will be presented as a late-breaker presentation at the 2026 Annual European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Sept. 30 – Oct. 3.
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie (NYSE: ABBV) today announced new research across its diverse dermatology portfolio to be presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, September 30 – October 3 in Vienna, Austria. The breadth of data from 60 abstracts, including three late-breaking presentations, reflects AbbVie's expanding portfolio across a wide spectrum of immune-mediated skin diseases, and includes the investigational compounds lutikizumab and zumilokibart, and approved therapi
AbbVie Says All Three Zumilokibart Dose Regimens Met Primary Endpoint With Significantly Greater EASI-75 Response Vs Placebo At Week 16 In Phase 2 APEX Part B Atopic Dermatitis Study
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
AbbVie (ABBV) closed the most recent trading day at $263.29, moving 1.12% from the previous trading session.
Defensive Dividends: 3 Companies Investors Can Rely On
Several members of the elite Dividend Kings club, including JNJ, KO, and ABBV, are known for dividend reliability, each with a long, consistent history of increasing payouts. The trio boasts a strong defensive nature given consumers' needs for their products no matter the backdrop.
Is Eli Lilly Stock a Good Fit For Your Portfolio Risk?
You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.84% on an annualized basis producing an average annual return of 15.37%. Currently, AbbVie has a market capitalization of $465.70 billion.
Amazon, Walmart Surplus Auctioneer Climbs Toward A Breakout; Stock Up 45%
The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.
Management Raised the Bar For Eli Lilly Stock; Does The Chart Agree?
Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval
The once-daily treatment reaches the U.S. market in October after improving motor-control measures across three Phase 3 studies.
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo
ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’
CNBC’s final trades: Weiss picked UnitedHealth, Lebenthal chose AbbVie after FDA approval, and Terranova backed Okta amid raised price targets.
Johnson & Johnson: Strong Catalysts, But I'm Staying At Hold
Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.
AbbVie And Valkai Collaborate To Accelerate Pace Of Scientific Innovation's Reach To Patients
AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
GOOGL, MA and ABBV headline today's research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.
FDA Nod For JUVMO Parkinson’s Drug Could Be A Game Changer For AbbVie (ABBV)
AbbVie recently received U.S. FDA approval for JUVMO (tavapadon) tablets, the first and only selective D1/D5 receptor agonist for adults with Parkinson’s disease, offering a new way to manage motor symptoms alongside existing levodopa-based regimens. This approval adds a differentiated mechanism within AbbVie’s neuroscience portfolio, potentially helping clinicians manage levodopa dose escalation and treatment-related complications in Parkinson’s care. We’ll now examine how JUVMO’s...
Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's?
AbbVie (ABBV) just secured U.S. FDA approval for JUVMO, a Parkinson's disease pill that targets D1/D5 receptors. This gives the neuroscience portfolio a new pillar supported by late stage efficacy and safety data. AbbVie shares have been trending higher, with a 30 day share price return of 4.23% and a year to date gain of 16.12%. Total shareholder return sits at 23.02% over one year and almost doubles over three years, suggesting momentum has been building as new approvals like JUVMO, RINVOQ...
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.
$85 Billion And Counting: JNJ Stock's Steady Cash-Return Habit
A healthcare giant sent a torrent of cash back to its owners, but the real story is what that money did, and did not, buy for the stock.
Top Research Reports for Alphabet, Mastercard & AbbVie
Alphabet's AI-led cycle is strengthening Search, Cloud and subscriptions, while rising investment and regulatory risks create uncertainty around returns.
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
ADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S. IPO that could raise up to $371.9 million. The San Diego-based RNA drug developer plans to offer 21.9 million shares at between $15 and $17 apiece and list on the Nasdaq under the […]
What Are Merck Stock Investors Overlooking?
If you own Merck (MRK) stock, the number to watch is the sales of one cancer drug family. KEYTRUDA family sales were $8.4 billion in the second quarter of 2026. That was about half of Merck's $16.6 billion in quarterly revenue. Management now expects KEYTRUDA’s U.S. growth to moderate, raising questions about whether the stock's recent run has fully priced in the transition.
Johnson & Johnson’s Next Growth Engine Is Taking Shape
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull case or the headwinds win.
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start
Key Stats for AbbVie StockCurrent Price: $264. 34Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA approved Juvmo (tavapadon), a once-daily Parkinson’s pill from AbbVie (ABBV), on Friday, September 25, according to Reuters.
AbbVie Just Won an FDA First in Parkinson's Disease
The FDA approved Juvmo as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with a U.S. launch planned for October.
AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo
AbbVie Inc (NYSE:ABBV) received approval from the U. S.
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says
FDA approves AbbVie's Juvmo for Parkinson's disease, the first D1/D5 agonist. U.S. launch set for Oct 2026. Get pricing and sales data.
U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide.
8 Of 11 Sectors Fall In Monday Trading As Defensives Lead
Three sectors are higher and eight are lower in Monday’s regular session, with defensive and cyclical sectors split across the top three positions. The leaders are separated rather than clustered.
AbbVie Receives FDA's Approval For JUVMO To Treat Adults with Parkinson's Disease
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth
AbbVie Inc. (NYSE:ABBV) and Iambic announced a multi-year collaboration to use Iambic’s AI platform to accelerate small-molecule drug discovery across immunology, neuroscience, and oncology. The partnership will use Iambic’s Enchant v3 model, which is trained on more than 6,000 molecular properties and is designed to evaluate multiple drug characteristics simultaneously. The companies will pursue candidates […]
Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.
How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield Trap
Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio shows how a much lower yield can generate far more income a decade from now than a double-digit payout ever could.
What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves?
AbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in ADARx ties AbbVie to RNA-based therapies being developed for certain rare disease indications. Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma. AbbVie's move into ADARx's IPO and the new EPKINLY approval both need weighing against the rest of our ABBV thesis. We have...
Best Dividend Kings: September 2026
Dividend Kings are underperforming SPY in September, with a -4.22% average return versus SPY's marginal gain.
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.
InMode: Hope Is Not An Effective Investment Strategy, But Neither Is Despair
InMode (INMD) stays rangebound as US sales slip; global growth and consumables stabilize. Read here for a detailed investment analysis.
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
U.S. FDA Approves Juvmo (Tavapadon) For Parkinson’s Disease In Adults On Sept 25, 2026
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
Is LLY Stock Cheaper Than It Looks?
At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.
Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money?
The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.
ADARx Pharmaceuticals raises $446 million in upsized IPO
The San Diego RNA drug developer sold 26.3 million shares at $17 apiece, with AbbVie investing up to $100 million in a concurrent private placement
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
RNAi drug specialist ADARx raises $446M IPO
ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgenelomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles.
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules
Iambic widens the discovery search, but AbbVie disclosed no targets, payment amounts or development timetable.
Can Eli Lilly Stock Catch Up To Rivals It Outgrows?
Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
AbbVie (NYSE: ABBV) announced today that Health Canada has issued a Notice of Compliance for EPKINLY® (epcoritamab) with a new follicular lymphoma (FL) indication. EPKINLY®, in combination with lenalidomide and rituximab, is indicated for the treatment of adult patients with relapsed or refractory Grade 1, 2, or 3a FL who have received at least one prior line of systemic therapy.6
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade
It would be hard for investors to replicate the company's return over the past decade.
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]
AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell'
AbbVie is rated a "Sell" with a $191 target, implying 27.7% downside from the current $264 price. Click here to read more about the ABBV stock.
What Is AbbVie No Longer Telling You?
AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.
What Is The Best Case For Pfizer Stock?
Pfizer's COVID products keep shrinking. The company's total revenue has been flat for a year. That makes the best case for this stock easy to miss. It does not rest on the medicines you already know Pfizer (PFE) for. It is not another round of cost cuts either. It rests on a smaller and faster part of the company. So where is that growth coming from.
Recent Filing Shows That Rep. Pete Sessions Sold Over $100K Worth of Apple Stock
A September filing shows that Representative Pete Sessions reported a sale in Apple (NASDAQ:AAPL), valued between $100,001 and $250,000. The transaction date is listed as September 22, 2026, with the report published on
2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie
Johnson & Johnson vs. AbbVie valuation: JNJâs P/E & PEGY premium looks justified by a strong balance sheet, buybacks, and more. Read the full analysis here.
AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis
AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ in polyarticular juvenile idiopathic arthritis for patients as young as two. Allergan Aesthetics launched AA Signature SKIN360 in the U.S., offering a multimodal digital platform for medical aesthetics consultations. AbbVie entered AI-focused collaborations with Iambic and the AISB Bind project to use advanced models in drug discovery and molecular binding prediction. The RINVOQ pediatric extension, AA Signature SKIN360...
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis. The approval covers patients who did not respond to, or could not tolerate, standard disease-modifying drugs. It is the eleventh indication Rinvoq holds in Europe. The Commission also cleared […]
AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis
ABBV's Rinvoq secures EU approval for pJIA in children, expanding ABBV's reach as clinical data show sustained improvements in disease activity.
Congressman with $11.5 Million in Trades Keeps Selling Stocks: Here’s the Latest Moves
A member of Congress continues to sell stocks, with no buys since 2024. Here are the latest names traded.
SBIO: Big Pharma Needs What This Fund Owns
The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on the SBIO ETF.
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
Could You Have Seen Merck Stock's Pipeline Run Coming?
Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for the S&P 500. It also beat Johnson & Johnson (JNJ), up 58%, and Eli Lilly (LLY), up 54%. The signs were public long before the run, in what management kept saying about its drug pipeline. The reported sales told a different story.
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.
Why Is JNJ Stock Beating Rivals That Grow Faster?
Johnson & Johnson (JNJ) stock has returned 58% over the past twelve months, second best in a group of six health care companies. Its revenue growth ranks only fourth of the six. Three peers grew faster and returned less, Eli Lilly among them. The price is a bet that the rest of the business keeps growing once shrinking STELARA sales stop dragging on the total.
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the global industry leader in aesthetics, today announced the U.S. launch of AA Signature™. Building on the program's successful international rollout and strong support from health care providers (HCPs), AA Signature is a collection of patient-centric, multimodal consultation approaches that leverage Allergan Medical Institute (AMI) resources and Allergan Aesthetics products. The program will launch with AA Signature™: SKIN360, its first pati
AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization
BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization
AbbVie Secures EU Approval for Rinvoq in Juvenile Arthritis
AbbVie (NYSE:ABBV) announced on Tuesday that the European Commission has approved Rinvoq (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis. The approval covers children aged two years and older who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
These companies are committed to rewarding shareholders.
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg tablet and weight-based 1 mg/mL oral solution) for the treatment of active polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
AbbVie Receives European Commission Approval Of RINVOQ For Children With Active Polyarticular Juvenile Idiopathic Arthritis Aged Two And Older
RINVOQ is now approved in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older who have responded inadequately to, or who are
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Iambic Therapeutics, an AI drug discovery company backed by Nvidia and the Qatar Investment Authority, filed to go public Monday.
How Much Do You Really Need Invested to Replace a $200,000 Salary With Dividends?
Replacing a top-tier salary with dividends sounds like a portfolio problem, but the yield you chase could cost you far more than the shares you buy. The answer depends on a tradeoff most investors never think to run.
Novo Nordisk shares plunge over 7% as new targets fail to reassure investors
Novo Nordisk (NYSE:NVO), the Danish drugmaker, saw its US-listed shares fall over 7% to $39.82 on Monday after new long-term targets failed to ease investor concerns about competition in the weight-loss drug market. The company said it aims to launch more than five multi-blockbuster drugs by...
Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations
Novo Nordisk's (NVO) US-listed shares declined as the Danish drugmaker unveiled its long-term growth
What Would It Take For Pfizer To Cut Its Dividend?
Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology. The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug
Rep. Pete Sessions Has Sold Up to $100K Worth Of AbbVie Stock: Here’s What You Should Know
An official report on September 18, 2026 reveals Representative Pete Sessions's recent sale of AbbVie (NYSE:ABBV) stock, valued between $30,002 and $100,000. The transaction took place on September 14, 2026, as per
AbbVie Enters Multi-Year Collaboration With Iambic To Accelerate Discovery And Development Of Small Molecule Therapies Across Immunology, Neuroscience And Oncology; Iambic To Receive Upfront Payment And Is Eligible For Milestone Payments And Tiered Royalties
The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates."We are excited about the purpose-built AI capabilities Iambic is bringing to
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
AbbVie's market-beating days don't seem to be over yet.
AbbVie (ABBV) Unveiled New VRAYLAR Data In Real World And Pediatric Care
AbbVie (NYSE:ABBV) shared new real-world and pediatric safety data for VRAYLAR in MDD and bipolar I at Psych Congress 2026. The findings covered routine clinical practice settings, including patients with complex comorbidities and underserved groups. Pediatric data for VRAYLAR added information on safety and use in younger patients with mood disorders. The fresh VRAYLAR real-world and pediatric results sit against a wider backdrop our research has uncovered. Check out 4 warning signs that...
What Would It Take For Eli Lilly Stock To Keep Climbing?
Eli Lilly (LLY) trades near $1,150, up about 52% over the past year, and is now worth more than a trillion dollars. At that size the easy read is that the big money has been made. But Lilly has barely started selling Foundayo, its oral obesity medicine, outside the United States. So how much is left? The scenario below starts from Lilly's own trailing numbers, but the growth, margin, and multiple it assumes are ours. It is not a forecast and not a price target.
Is Johnson & Johnson Stock Expensive, Or Is STELARA Hiding The Real Price?
Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.
Merck Stock Nearly Doubled Without A Change In Its Revenue Growth
Merck (MRK) stock returned about 87% over the past twelve months, climbing from roughly $79 to about $147. Nothing in the year's results looks like that. The medicines Merck sells today grew at their usual pace. Investors spent the year repricing what comes next.
AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, 2026, to shareholders of record as of October 15. There is no new increase this time, since AbbVie has kept its quarterly dividend at $1.73 throughout 2026. Still, the latest declaration confirms the higher payout […]
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
AbbVie (NYSE: ABBV) today presented new VRAYLAR® (cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I). The findings reinforce that the efficacy established in clinical trials translates to effectiveness in the broader, more clinically complex patient populations healthcare providers treat every day.
5 Stocks, 5 Different Industries, 1 Thing in Common: Reliable Income
A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing the highest yield.
The Dividend Kings Ranked By Quality Scores (September 2026)
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges.
Can Volume Keep Covering Eli Lilly's Price Cuts?
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
How Large Does Your Portfolio Need to Be to Generate $10,600 a Month?
The capital required to replace a professional salary with investment income swings by more than $2 million depending on one decision, and most investors default to the wrong tier without realizing it.
AbbVie Stock Just Posted a 74% Response Rate in Myeloma. Here’s What It Means for the Stock in 2026
Key Stats for AbbVie StockCurrent Price: $263. 04Target Price (Mid): ~$361Street Target: ~$279Potential Total Return: ~37% (over ~4.
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningfu
What Happens To AbbVie Stock If SKYRIZI Slows Down?
AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink. The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.
Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced results from two single-center clinical studies evaluating targeted skincare regimens alone and in combination with DiamondGlow® dermabrasion treatments in individuals taking medical weight loss (MWL) medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Presented at the Science of Skin Summit (SSS), Sept. 17-20, 2026, in Austin, Texas, the studies showed statistically significant, investigator-assessed
AbbVie (ABBV) Stock Looks Undervalued On Future Cash Flow
AbbVie has delivered a powerful run over the past several years, and the current share price of US$262.51 reflects significant confidence in its ability to keep turning today’s drug portfolio and pipeline into future cash. The open question for you as an investor is whether those cash flows, when you project and discount them, line up with where the stock now trades. AbbVie has returned 196.4% over the past 5 years, which raises the stakes on whether its future cash generation fully supports...
Is Pfizer's New Business Big Enough To Carry The Old One?
Pfizer (PFE) trades at about 95% of its 52-week high. The business that has to justify that price, the medicines it has launched and acquired, is still only about a fifth of the company. The stock returned roughly 24% over the past year against about 17% for the S&P 500, so investors have so far given the handoff the benefit of the doubt. It is a large bet on a small slice.
Should You Judge JNJ Stock Without STELARA?
Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500. The change worth noticing over that stretch is quieter than the price. Management said sales still rose 5.6% despite a STELARA drag of about 460 basis points. Management is encouraging investors to evaluate the company's underlying momentum by presenting growth rates that exclude STELARA alongside its reported figures.
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
ABBV's neuroscience portfolio has broadened across psychiatry, migraine and Parkinson's, driving strong growth and raising its 2026 outlook.
Is AbbVie the Best Dividend King to Buy in September?
It is certainly a good Dividend King to buy in September.
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck Stock: Is The $70 Billion Pipeline Worth the Premium?
A powerful drug pipeline is fueling a stock trend that ranks in the top 6% of US stocks worth more than $1 billion, but the ticket price for investors is steep and the clock is ticking on its biggest star.
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NYSE:ABBV)’s ratings from Peer Perform, with Wolfe assigning them similar $300 price targets. The firm’s logic in each case was based on a comparable set of factors: pipelines that the market appears to […]
AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s established SKYRIZI and RINVOQ franchises. Speaking at a Morgan Stanley event, Chairman and Chief E
AbbVie Inc. (ABBV) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AbbVie Inc. (ABBV) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:00 AM EDTCompany ParticipantsRobert Michael - CEO &...
AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
AbbVie (NYSE: ABBV), together with BioLabs University of Toronto, today announced the opening of applications for the AbbVie Biotech Innovators Award during the Life Sciences Ontario Ideas to Action Forum in Toronto. The award aims to support the growth of Ontario's life sciences sector by helping promising early-stage biotechnology companies accelerate the development of innovative healthcare solutions.
AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
AbbVie (NYSE: ABBV), a global pharmaceutical leader, and the PGA TOUR today announced a partnership naming AbbVie the Official Pharmaceutical Sponsor of the PGA TOUR and the 2026 Presidents Cup. Through this new partnership, AbbVie introduces Birdies for Brain Health, a multi-year, purpose-driven campaign that turns birdies into more than a score by raising awareness and advancing support for people living with brain health conditions and their care partners.
Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will bring its scientific leadership to the 2026 Science of Skin Summit (SSS), taking place Sept. 17-20 in Austin, Texas, through expert programming and on-site education focused on skin longevity, aging biology, regenerative aesthetics and emerging exosome research. Company R&D leaders will examine the hallmarks of aging, discuss how rigorous evidence can inform skincare innovation and introduce the FACTS Principles developed by SkinMedica®,
AbbVie Exec Says Plans To Start Enrolling Apogee's Zumilokibart This Year, Targets Launch In Early 2030; Says Will Present Late-stage Data For Blood Cancer Drug Etentamig At International Myeloma Society Meeting Later In September
https://event.webcasts.com/starthere.jsp?ei=1773801&tp_key=756e5e03ad&tp_special=8
AbbVie Exec Says Apogee Fits 'Very Nicely' With Its Business Development Approach; Says Existing Portfolio Provides 'Clear Line Of Sight' To Very Strong Growth Well Into Next Decade
- conference call
These 3 Income-Oriented ETFs Are All You Need For Retirement
Retirement income update: Why the 4% rule can fail in todayâs market and how a yield-first ETF mix may pay ~$48k/$1M. Read the full analysis here.
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.
SCHD’s 0.06% Fee Hides the Real Cost: March’s 31% Reshuffle Sold Two Top-10 Holdings Out From Under Holders
SCHD's 0.06% expense ratio gets all the attention, but something that happened quietly in March may have cost dividend investors far more than a decade of fees combined.
How Much of a $9,100 Monthly Dividend Paycheck Do You Actually Keep After Taxes?
Two portfolios generating identical dividend income can leave one investor thousands of dollars richer than the other, and the difference has nothing to do with yield. The culprit is hiding inside your 1099-DIV.
Is This LLY Stock Dip Big Enough To Be Worth Buying?
Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.
Why Is Pfizer Stock Paying You So Much To Wait?
Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management's answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.
AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.
AbbVie’s Latest Migraine Success Strengthens its Growth Story
AbbVie Inc. (NYSE:ABBV) said its migraine treatment atogepant, sold as Qulipta in the U.S., met the main goal of a late-stage study evaluating its ability to prevent migraines associated with the menstrual period. Patients taking the drug experienced an average of 0.8 fewer migraine days than those receiving placebo over three menstrual cycles. The treatment […]
Do the Math: Tax Man Goes Away When You Own These Dividend Stocks in a Roth IRA
A Roth IRA can strip the tax burden from even the highest-yielding dividends, but only if you put the right stocks inside it. Five blue chips with records stretching back decades make a compelling case for why account placement matters as much as stock selection.
How Much You Need Invested to Cover Your Medicare Premiums With Dividend Income
Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your specific income bracket demands.
How Much Does a 61-Year-Old Need Invested to Collect $8,600 a Month for Life?
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever promising to repeat it.
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock?
AbbVie's dividend is a very appealing factor.
Is AbbVie Stock Actually Overpriced?
AbbVie (ABBV) grew revenue 10.4% over the past twelve months and turned 33.9% of it into operating profit, second only to Eli Lilly among its peers on both counts. Its stock returned 24.9% over the same twelve months, fifth of the six. What the business delivered and what the market paid for it have come apart.
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
There are currently no targeted therapies specifically approved for menstrual migraine, though other anti-migraine drugs are used off-label in this indication.
How Much Dividend Income Can You Buy With $250,000?
A $250,000 rollover sounds like a clean starting point until you realize yield alone is not the whole story, and only one name on this roster actually clears the current Treasury rate. Here is what the math, the coverage ratios, and 43-year dividend streaks reveal about building real income from a common account balance.
What's Going On With AbbVie Stock Friday?
AbbVie shares are edging higher Friday following Thursday's positive Phase 3 trial results for its menstrual migraine drug, atogepant.
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
Merck Stock Vs. LLY: Why Is The Slower Grower More Expensive?
In the high-stakes world of big pharma, the slower-growing giant now commands the higher price, forcing investors to decide what that premium is truly buying.
AbbVie Declares Quarterly Dividend
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
AbbVie Gains as Qulipta Opens a New Migraine Market
The Phase 3 victory supports intermittent treatment, potentially expanding use without requiring continuous daily dosing.
JNJ Stock: Is the Rally Running Out of Steam?
A healthcare titan is in a full sprint, but a recent stumble has investors asking if the best part of the race is already over.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Pfizer Stock Or Zoetis: Is The Comeback Worth Paying Up For?
If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
Why Has AbbVie Gone Quiet About Humira?
AbbVie (ABBV) has returned 23.3% over the past year, ahead of the S&P 500's (SPY) 18.5%, and the business behind that return has changed shape. Humira, the drug whose decline management once explained, took one sentence on the July 2026 earnings call. What that sentence no longer contains is the part a holder should look at.
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults.1 These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks.
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.
HSBC Maintains Buy on AbbVie, Raises Price Target to $315
HSBC analyst Rajesh Kumar maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $300 to $315.
Pfizer: Firing On All Cylinders
Pfizer's pipeline strength is evident, especially with berobenatide and Vyndamax, providing a bridge over the 2028 LOE trough. Read why PFE stock is a buy.
AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo
These results reinforce AbbVie's scientific expertise in migraine and its focus on advancing solutions for people living with complex and disabling migraine attacks."These positive Phase 3 LUNA results represent
Amgen's Forward Multiple Looks Cheap Until You Price The Margins It Assumes
Amgen (AMGN) trades at about $393 a share. On the last twelve months of adjusted earnings, that is a trailing multiple of about 23.3 times. With Prolia and XGEVA sales falling to biosimilar rivals, the multiple looks full. What the forecast underneath it asks for is a wider margin while the company funds MariTide.
Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives the company another route into a market where more than 8.4 million people are affected by psoriasis, according to J&J. Icotyde could appeal to patients who prefer a pill over an injectable treatment, potentially […]
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee’s promising inflammatory and immunology (I&I) pipeline into AbbVie’s commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its […]
What Eli Lilly Was Telling You While It Rationed Its Own Launches
Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It was deliberately selling less medicine than people wanted to buy, and it kept saying so out loud.
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.17% on an annualized basis producing an average annual return of 14.76%. Currently, AbbVie has a market capitalization of $445.73 billion.
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
VERAXA Biotech Designates Raju Willener as CFO
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of […] The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.
AbbVie Inc. (ABBV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 10:15 AM EDTCompany ParticipantsScott Reents - Executive VP &...
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
AbbVie Exec Says Balance Sheet And Growth Runway Allow Company To Consider Both Early- And Late-Stage Business Development Opportunities
- conference call
Billionaire Israel Englander Is Doubling Down on These 2 Outstanding Dividend Stocks. Should You?
Dividend seekers can hardly go wrong with these companies.
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note
In the most recent trading session, AbbVie (ABBV) closed at $248.78, indicating a -2.99% shift from the previous trading day.
Is AbbVie Stock Too Reliant On Skyrizi?
AbbVie (ABBV) trades at $256.46, roughly 96% of its 52-week high, after returning 24.1% over the past twelve months against 19.7% for the S&P 500. That price buys a business where about a third of guided 2026 revenue comes from one drug. The market reads that concentration as strength. It is worth reading it the other way too.
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now
Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.
What Merck Stopped Saying About GARDASIL Should Change What You Watch
Merck (MRK) has returned about 85% over the past year and at about $150 trades roughly 4% below its 52-week high. A year ago, management spent earnings calls managing fallout from a steep drop in GARDASIL sales. That problem has left the lead. What management opens with instead is a much larger claim, and it settles years from now.
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back
JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.
Assessment of the Rheumatoid Arthritis Market 2026-2036 Featuring Rise Therapeutics, Taiho Pharmaceutical, Abbvie, Eli Lilly/Incyte, and AstraZeneca
Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention create room for innovationDublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. Rheumatoid Arthritis Market Forecast to Reach New Growth Milestones Through 2036, Driven by Targeted Therapies and Expanding Patient Demand The report provides a comprehensive analysis of the rheumatoid
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)
Owning these dividend stocks could be a simple way to make money over the long term.
ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its Board
ANI Pharmaceuticals (NasdaqGM: ANIP) appointed biotechnology executive Henry Gosebruch to its Board of Directors. Gosebruch previously held leadership roles at Lakefront Biotherapeutics, Neumora Therapeutics, and AbbVie. Board member Muthusamy (Samy) Shanmugam resigned from the Board and will continue in key operational roles at ANI Pharmaceuticals. This kind of board refresh is not unique to ANI Pharmaceuticals, and investors who want broader exposure to companies shaped closely by their...
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.
Lilly (LLY) Down 2.7% Since Last Earnings Report: Can It Rebound?
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Amazon's diversified growth and AI push, AbbVie's pipeline, Alibaba's cloud gains and Lulu's improving margins shape these analyst picks.
Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.
AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma
AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)
AbbVie is supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. Find out why ABBV stock is a Buy.
AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]
The "Untouchable" List: Stocks That Short Sellers Won't Dare Bet Against
Why Short Sellers Are Running Scared from These Stocks
Top Analyst Reports for Amazon, AbbVie & Alibaba
Amazon, AbbVie and Alibaba face contrasting growth drivers and challenges, from AI investment and drug launches to costly spending cycles.
Sector Update: Healthcare Stocks Edge Higher Late Afternoon
Healthcare stocks were slightly higher late Thursday afternoon, with the NYSE Healthcare Index incre
AbbVie Touts Positive Data For Multiple Myeloma Drug
AbbVie Inc. (NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or refractory multiple myeloma. The study demonstrated that the drug outperformed standard therapies, meeting its primary goals for objective response rate and progression-free survival. Read Also: Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report Efficacy And Trial Metrics At a median follow-up of 11.4 months, resear
Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
ABBV Stock Has Returned $62 Billion To Shareholders. Should You Care?
A pharma giant delivered substantial cash returns to shareholders while outperforming the broader market. Here is a breakdown of AbbVie's cash-return capacity, and the key commercial metric supporting its durability.
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.
ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
AbbVie's Skyrizi, Rinvoq and neuroscience drugs drive growth, but Humira erosion, oncology and Aesthetics remain key headwinds.
AbbVie could take BiTE of Tecvayli market share on Phase III MM win
If approved, etentamig would join the increasingly competitive multiple myeloma market, which has seen the addition of several targeted therapies in recent years.
AbbVie Completes Acquisition of Apogee Therapeutics
AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available therapies (SAT) in patients with triple-class exposed (proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody) relapsed/refractory multiple myeloma (RRMM). The study met its dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS). Full results will
AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Management will participate in a fireside chat at 9:00 a.m. Central time.
AbbVie Affirms FY2026 Adj EPS Guidance of $13.87-$14.07 vs $14.08 Est
AbbVie (NYSE:ABBV) affirms FY2026 Adj EPS guidance from $13.87-$14.07 to $13.87-$14.07 vs $14.08 analyst estimate..
AbbVie Affirms Q3 Adj EPS Guidance of $3.84-$3.88 vs $3.84 Est
AbbVie (NYSE:ABBV) affirms Q3 Adj EPS guidance from $3.84-$3.88 to $3.84-$3.88 vs $3.84 analyst estimate..
Abbvie Announces Topline Results From The Phase 3 Cervino Trial Showing Etentamig Significantly Improved Response Rate And Progression-Free Survival In Patients With Relapsed/Refractory Multiple Myeloma; Etentamig Achieves 74% Orr And 60% Risk Reduction In Phase 3 Cervino Trial; Etentamig Demonstrates Low Rates Of Cytokine Release Syndrome And Fatal Infections; Phase 3 Cervino Study Met Dual Primary Endpoints; Full Results To Be Presented Sept 23-26
Etentamig, an investigational asset, achieved a significantly improved objective response rate (ORR, 74%) and a 60% risk reduction in disease progression or death (progression-free survival, hazard ratio 0.40) versus
AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032
AbbVie (NYSE:ABBV) today announced that it expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-14 | Donoghoe Nicholas | -32,710 | - | - |
| 2026-08-14 | Donoghoe Nicholas | -32,710 | $250 | $8,177,500 |
| 2026-08-14 | Donoghoe Nicholas | +32,710 | $79.02 | $2,584,744 |
| 2026-06-30 | Quaggin Susan E | +62 | $251.64 | $15,602 |
| 2026-06-30 | RAPP EDWARD J | +134 | $251.64 | $33,720 |
| 2026-05-08 | Quaggin Susan E | +1,118 | - | - |
| 2026-05-08 | Davis Jennifer L. | +1,118 | - | - |
| 2026-05-08 | MEYER MELODY B | +1,118 | - | - |
| 2026-05-08 | BURNSIDE WILLIAM H.L. | +1,118 | - | - |
| 2026-05-08 | Hart Brett J | +1,118 | - | - |
| 2026-05-08 | Roberts Rebecca B | +1,118 | - | - |
| 2026-05-08 | FREYMAN THOMAS C | +1,118 | - | - |
| 2026-05-08 | WADDELL FREDERICK H | +1,118 | - | - |
| 2026-05-08 | FALK THOMAS J | +1,118 | - | - |
| 2026-05-08 | RAPP EDWARD J | +1,118 | - | - |
| 2026-05-08 | AUSTIN ROXANNE S | +1,118 | - | - |
| 2026-03-31 | Quaggin Susan E | +71 | $217.49 | $15,442 |
| 2026-03-31 | Alpern Robert J | +35 | $217.49 | $7,612 |
| 2026-03-31 | RAPP EDWARD J | +155 | $217.49 | $33,711 |
| 2026-03-04 | Purdue David Ryan | -5,230 | $233.56 | $1,221,519 |
| 2026-03-02 | Siatis Perry C | -2,600 | $235.26 | $611,676 |
| 2026-03-02 | Siatis Perry C | -10,291 | $234.66 | $2,414,886 |
| 2026-03-02 | Siatis Perry C | -5,777 | $233.51 | $1,348,987 |
| 2026-02-27 | Purdue David Ryan | -2,108 | $232.08 | $489,225 |
| 2026-02-27 | Crum Demetris D | -1,594 | $232.08 | $369,936 |
| 2026-02-27 | Purdue David Ryan | -2,692 | $232.08 | $624,759 |
| 2026-02-27 | Thakkar Roopal | -8,037 | $232.08 | $1,865,227 |
| 2026-02-27 | Siatis Perry C | -14,850 | $232.08 | $3,446,388 |
| 2026-02-27 | Reents Scott T | -21,638 | $232.08 | $5,021,747 |
| 2026-02-27 | Donoghoe Nicholas | -12,874 | $232.08 | $2,987,798 |
| 2026-02-27 | Stewart Jeffrey Ryan | -23,812 | $232.08 | $5,526,289 |
| 2026-02-27 | Michael Robert A. | -36,523 | $232.08 | $8,476,258 |
| 2026-02-27 | SALEKI-GERHARDT AZITA | -16,309 | $232.08 | $3,784,993 |
| 2026-02-25 | Siatis Perry C | -7,292 | $192.86 | $1,406,335 |
| 2026-02-25 | Siatis Perry C | -7,775 | $175.28 | $1,362,802 |
| 2026-02-25 | Siatis Perry C | -7,314 | $149.62 | $1,094,321 |
| 2026-02-25 | Siatis Perry C | -22,381 | $230 | $5,147,630 |
| 2026-02-25 | Siatis Perry C | +7,292 | $192.86 | $1,406,335 |
| 2026-02-25 | Siatis Perry C | +7,775 | $175.28 | $1,362,802 |
| 2026-02-25 | Siatis Perry C | +7,314 | $149.62 | $1,094,321 |
| 2026-02-18 | Crum Demetris D | +13,406 | - | - |
| 2026-02-18 | Crum Demetris D | +1,244 | - | - |
| 2026-02-18 | Crum Demetris D | +1,216 | - | - |
| 2026-02-18 | Purdue David Ryan | +4,875 | - | - |
| 2026-02-18 | Purdue David Ryan | +1,384 | - | - |
| 2026-02-18 | Purdue David Ryan | +1,292 | - | - |
| 2026-02-18 | Purdue David Ryan | +890 | - | - |
| 2026-02-18 | Purdue David Ryan | +2,505 | - | - |
| 2026-02-18 | Thakkar Roopal | +21,937 | - | - |
| 2026-02-18 | Thakkar Roopal | +6,638 | - | - |
| 2026-02-18 | Thakkar Roopal | +3,346 | - | - |
| 2026-02-18 | Thakkar Roopal | +2,138 | - | - |
| 2026-02-18 | Thakkar Roopal | +6,015 | - | - |
| 2026-02-18 | Siatis Perry C | +19,500 | - | - |
| 2026-02-18 | Siatis Perry C | +5,808 | - | - |
| 2026-02-18 | Siatis Perry C | +5,628 | - | - |
| 2026-02-18 | Siatis Perry C | +5,792 | - | - |
| 2026-02-18 | Siatis Perry C | +16,290 | - | - |
| 2026-02-18 | Reents Scott T | +21,937 | - | - |
| 2026-02-18 | Reents Scott T | +7,260 | - | - |
| 2026-02-18 | Reents Scott T | +7,606 | - | - |
| 2026-02-18 | Reents Scott T | +8,910 | - | - |
| 2026-02-18 | Reents Scott T | +25,062 | - | - |
| 2026-02-18 | Donoghoe Nicholas | +20,312 | - | - |
| 2026-02-18 | Donoghoe Nicholas | +6,222 | - | - |
| 2026-02-18 | Donoghoe Nicholas | +5,172 | - | - |
| 2026-02-18 | Donoghoe Nicholas | +4,632 | - | - |
| 2026-02-18 | Donoghoe Nicholas | +13,031 | - | - |
| 2026-02-18 | Stewart Jeffrey Ryan | +26,812 | - | - |
| 2026-02-18 | Stewart Jeffrey Ryan | +8,988 | - | - |
| 2026-02-18 | Stewart Jeffrey Ryan | +9,432 | - | - |
| 2026-02-18 | Stewart Jeffrey Ryan | +9,266 | - | - |
| 2026-02-18 | Stewart Jeffrey Ryan | +26,063 | - | - |
| 2026-02-18 | Michael Robert A. | +81,251 | - | - |
| 2026-02-18 | Michael Robert A. | +22,124 | - | - |
| 2026-02-18 | Michael Robert A. | +14,452 | - | - |
| 2026-02-18 | Michael Robert A. | +12,030 | - | - |
| 2026-02-18 | Michael Robert A. | +33,833 | - | - |
| 2026-02-18 | SALEKI-GERHARDT AZITA | +20,312 | - | - |
| 2026-02-18 | SALEKI-GERHARDT AZITA | +6,638 | - | - |
| 2026-02-18 | SALEKI-GERHARDT AZITA | +7,074 | - | - |
| 2026-02-18 | SALEKI-GERHARDT AZITA | +6,058 | - | - |
| 2026-02-18 | SALEKI-GERHARDT AZITA | +17,041 | - | - |
| 2025-12-31 | Quaggin Susan E | +68 | $228.49 | $15,537 |
| 2025-12-31 | Alpern Robert J | +34 | $228.49 | $7,769 |
| 2025-12-31 | RAPP EDWARD J | +147 | $228.49 | $33,588 |